EZZ 11.4% $2.03 ezz life science holdings limited

Q4 looks to me much more indicative on the underlying...

  1. 4,131 Posts.
    lightbulb Created with Sketch. 440
    Q4 looks to me much more indicative on the underlying performance than Q3.

    The company had a cash flow from operation of 2 m$ during Q3, thanks to a large growth of their cash receipts (+ 111 % yoy).
    But, this cash flow was boosted by a major one off : "a substantial part of the cash inflow comes from delayed payments" (cf company Q3 quarterly disclosure).

    During Q4, the cash flow seems to be much more explained by the growth of the business : cash receipt growth was + 70 % yoy, with no mention by the company of a major one off effect in their cash receipt.
    It is also the reason why it is difficult to compare Q4 cash receipts with Q3 cash receipts (apart from the possible seasonality).
    The best indicator would be to compare Q4 revenues with Q3 revenues. Unfortunately, the company did not disclose these elements.
 
watchlist Created with Sketch. Add EZZ (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.